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Vaccination with outer surface protein A (OspA) of Borrelia burgdorferi prevents subsequent
infection and disease in both laboratory animals and humans with high efficacy. OspA-based
immunity, however, does not affect established infection due to the loss of OspA expression
in the vertebrate host. We show here that repeated passive transfer of mouse and/or rabbit
immune sera to recombinant GST-OspC fusion protein resulted in a dose-dependent resolu-
tion (1) of fully established arthritis and carditis as well as infection in needle-challenged
C.B-17 SCID and (2) of infection in both experimentally and tick-infected BALB/c mice.
Unexpectedly, active immunization of disease-susceptible AKR/N mice with GST-OspC only
led to prevention but not resolution of disease and infection, in spite of high serum titers of
OspC-specific Ab and the expression of ospC in tissue-derived spirochetes. The data sug-
gest that the efficacy of OspC antibody-mediated immunity depends on the immunological
history of the recipient and/or environment-dependent regulation of OspC surface expres-
sion by spirochetes in vivo. The results encourage further attempts to develop therapeutic
vaccination protocols against Lyme disease.
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Immune serum p.i.: Postinfection RT: Reverse transcrip-
tion
1 Introduction
Lyme borreliosis is a frequent vector-borne infection
caused by the spirochete Borrelia burgdorferi [1]. One of
the puzzles of this multisystemic disease is the failure of
men and mice to clear infection in many cases, despite
pronounced humoral and cellular immunity to the infect-
ing agent [1–4]. This is even more compelling since
immune sera (IS) from experimentally and naturally
infected mice are able to protect naive recipients from
infection [5–7]. Further studies revealed that protective
immunity against infection is mediated by Ab to various
outer surface proteins (Osp) of B. burgdorferi, including
OspA, B and C, and can be achieved by passive and
active immunization [5, 8–11].
Of the Osp known so far, OspA has been the most promis-
ing vaccine candidate against Lyme disease [12]. This is
emphasized by the recent phase III clinical trials with over
10 000 individuals in the United States, which revealed a
nearly 80 % protection of recipients against infection [13,
14]. However, the OspA-based vaccine is only applicable
for prevention but not treatment of established infection
[5, 15, 16]. The reason for that is unclear, but probably due
to the fact that OspA is mainly expressed by spirochetes
within ticks, and down-regulated upon their transmission
to mammalian hosts [17, 18].
In contrast to OspA, OspC appears to be expressed in
spirochetes, at least temporarily, in the vector [17] and
the vertebrate host [18]. OspC is also immunogenic,
because patients with Lyme disease as well as naturally
or experimentally (low dose: p 103 spirochetes) infected
mice readily produce Ab to OspC, but if at all, only occa-
sionally to OspA [1, 6, 7]. Active immunization of gerbils
and laboratory mice with recombinant OspC leads to
their complete protection against experimental challenge
and/or tick-borne infection with homologous B. burgdor-
feri isolates [11, 19, 20].
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We have recently found a close correlation between high
titers of serum anti-OspC Ab and resolution of infection
in mice [16]. This suggests that, in principle, spirochetes
are accessible and susceptible to OspC-specific Ab
within affected tissues. Subsequent studies showed that
passive transfer of OspC-specific mouse IS into experi-
mentally infected SCID mice leads to protection as well
as resolution of chronic arthritis and carditis, and clear-
ance from infective spirochetes [16]. However, a similar
study with contrasting results indicates that the protec-
tive capacity of OspC-specific Ab seems to critically
depend on the nature of the immunogen used [21].
We have now studied in more detail therapeutic vaccina-
tion against established B. burgdorferi infection using
OspC, and have analyzed the tissue localization of spiro-
chetes and mRNA expression of OspC during infection.
2 Results
2.1 Protective potential of mouse and rabbit
immune sera to OspC
In light of previous conflicting results [16, 21], we have
re-examined two preparations of OspC from strain ZS7,
i.e. the recombinant glutathione S-transferase-OspC
fusion protein (GST-OspC) and its rOspC (lipid free) por-
Table 1. Prevention of experimental B. burgdorferi infection in C.B-17 SCID mice by passive transfer of OspC-specific ISa)
Experiment Source of immune serum Treatment Dose Clinical arthritis Ear cultureb)
1 BALB/c – – 3/3 3/3
anti-GST-OspC 30 ? g 0/3 0/3
3 ? g 0/3 0/3
0.3 ? g 1/3 1/3
2 BALB/c – – 3/3 3/3
anti-GST 50 ? l, undiluted 3/3 3/3
anti-GST-OspC 3 ? g 0/3 0/3
3 BALB/c – – 3/3 3/3
anti-GST-OspC 3 ? g 0/3 0/2
anti-rOspC 3 ? g 3/3 3/3
4 Rabbit – – 3/3 3/3
anti-GST-OspC 30 ? g 0/3 0/3
3 ? g 2/3 2/3
0.3 ? g 3/3 3/3
a) Pooled mouse or rabbit IS generated to GST-OspC or rOspC were passively transferred at indicated doses into C.B-17 SCID
mice 1 h before experimental s.c. infection with 103 B. burgdorferi strain ZS7. Control mice received mouse IS specific for GST
or remained untreated.
b) Spirochete re-cultivation from ear biopsies was done on day 32 p. i. for experiments 1, 2 and 3 and on day 21 p. i. for
experiment 4, respectively.
tion for their immunogenicity and ability to induce pro-
tective Ab in BALB/c mice. With both protocols, animals
seroconverted; pooled IS from mice repeatedly chal-
lenged with GST-OspC (3×) or rOspC (4×) contained
167 ? g/ml and 66 ? g/ml OspC-specific Ab, respectively.
As shown in Table 1, passive transfer of 30 and 3 ? g, but
not of 0.3 ? g of GST-OspC-specific or 3 ? g of rOspC-
specific Ab into C.B-17 SCID mice 1h before challenge
led to complete protection against disease and infection
in all 12 mice in three independent experiments. In addi-
tion, the state of infection was monitored by recultivating
of spirochetes from ear skin biopsies, a target organ con-
sistently infected in laboratory mice [3, 22] and in reser-
voir hosts [23]. Furthermore, mouse IS to GST-OspC –
and, as shown before [5, 16], to recombinant outer sur-
face lipoprotein A (rLip-OspA) – completely prevented
development of clinical arthritis and infection in all 5 C.B-
17 SCID mice tested upon tick challenge (Table 2; [9, 10,
16]). As shown before, IS to rLiP-OspA had a similar pro-
tective potential.
In essence, similar results were obtained with rabbit IS to
GST-OspC, which, however, showed lower levels of pro-
tective potential (Table 1, Exp. 4). Repeated administra-
tion of either 360 ? g (4×) or 1800 ? g (4×) Ab to OspC
starting at day 30 postinfection (p.i.), resulted in partial or
nearly complete resolution, respectively, of fully estab-
lished clinical arthritis (data not shown) and carditis
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Table 2. Prevention of tick-borne B. burgdorferi infection of
C.B-17 SCID mice by passive transfer of GST-OspC- or
rLip-OspA-specific ISa)
Immune
serum
Clinical arthritis
(days p. i.)
Ear culture
(days p. i.)
68 100 40 100
None 2/2 2/2 2/2 2/2
Anti-rLip-
OspA
0/4 0/4 0/4 ND
Anti-GST-
OspC
0/5 0/5 0/5 ND
a) C.B-17 SCID mice were treated with GST-OspC- or rLip-
OspA-specific IS (10 ? g/mouse) and challenged 1 h later
with previously infected (B. burgdorferi, strain ZS7)
nymphal ticks. Control mice remained untreated.
Table 3. Prevention and resolution of experimental B. burgdorferi infection in C.B-17 SCID mice by passive transfer of OspC-
specific rabbit ISa)
Rabbit
immune
serum
( ? g/mouse)
Interval of
treatment
(days p. i.)
Mouse Clinical arthritis (days p. i.)b) Histopathological examination of heartc) Ear culture
(days p. i.)
30 87 115 155 dayd) pericard. myocard. endocard. 30 73 115
1 –/– –/– 88 – – – – – ND
Anti-GST-OspC –1h 2 –/– –/– –/– –/– 155 – – – – – ND
(30 ? g) 3 –/– –/– –/– –/– 155 – – – – – ND
1 ++/++ ++/++ 88(44) ++ ++ + + + ND
NRS 30,35,39,44 2 ++/++ ++/++ ++/++ +/+ 155(111) ++ ++ + + + ND
3 ++/++ ++/++ ++/++ +/+ 155(111) ++ ++ + + + ND
1 ++/++ ±/± 88(44) – – – + – ND
Anti-GST-OspC 30,35,39,44 2 ++/++ ±/± (±) / (±) ±/+ 155(111) + + – + – +
(360 ? g) 3 ++/++ ±/ (±) ++/++ ++/+ 155(111) ++ + – + – +
1 ++/++ (±) /± 88(44) ± – – + – ND
Anti-GST-OspC 30,35,39,44 2 ++/++ ±/ (±) (±) /± (±) / (±) 155(111) – – – + – –
(1800 ? g) 3 ++/++ ±/± ±/ (±) +/ (±) 155(111) – – – + – –
a) C.B-17 SCID mice were treated with the indicated doses of rabbit anti-GST-OspC IS either before (–1 h) or starting at day 30
p. i. In the latter case, control mice received normal rabbit serum (NRS). Recipients were infected s.c. with 103 B. burgdorferi
strain ZS7.
b) Scoring of clinical arthritis in the right and left tibiotarsal joints: ++, severe; +, moderately severe; ±, mild swelling; (±), redding;
–, no clinical signs.
c) Scoring for histopathological examinations of heart: ++, extensive; +, severe; ±, moderate; –, no lesion.
d) Day of histopathological examination p. i. (days after last Ab treatment).
(Table 3 and Fig. 1). Histopathological analysis of heart
tissue of infected mice showed that the massive inflam-
matory lesions, which were mainly associated with the
valvulae regions but much less pronounced within the
myocardium, were partially or completely resolved, when
tested with either low (360 ? g; 4×) or high (1800 ? g, 4×)
amounts of rabbit IS, respectively (Fig. 1). Again, as
shown before with OspC-specific mouse IS [16], C.B-17
SCID mice treated with IS to GST-OspC (30 ? g Ab) 1h
prior to experimental challenge with spirochetes did not
develop valvulitis or mycarditis. Furthermore, after treat-
ment of infected C.B-17 SCID mice with 360 ? g/ml of
OspC-specific rabbit Ab, spirochetes were not detect-
able at day 73 p.i. (day 44 after last treatment) but reap-
peared at day 115 p.i. (day 86 after last treatment; Table
3). In contrast, when treated with fivefold higher concen-
tration of the same rabbit IS (1800 ? g Ab), spirochetes
could not be recovered from ear biopsis at either of the
two time points (Table 3).
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Figure 1. Histopathological examination of heart (day 155 p.i.) from B. burgdorferi-infected C.B-17 mice following either prophy-
lactic or therapeutic treatment with rabbit IS specific for GST-OspC. One set of representative sections is shown out of four sec-
tions with similar results, taken at different sites of each paraffin-embedded heart sample.
2.2 Potential of anti-GST-OspC IS to prevent or
resolve experimental and tick-borne infection
in BALB/c mice
BALB/c mice were given GST-OspC-specific IS either
before (–1h; 10 ? g Ab, 1×) or repeatedly (30 ? g Ab, 4× in
3-day intervals) after experimental challenge, starting at
either day10, 20 or 40 p.i. (Fig.2A) and the state of infec-
tion was determined by recultivation of spirochetes from
ear biopsy specimens. Passive transfer of GST-OspC-
specific IS (10 ? g Ab) prior to challenge completely pro-
tected all five mice against infection (Table4). Most nota-
bly, sterile immunity was also achieved in all but two (18/
20) infected BALB/c mice, independent of whether treat-
ment with GST-OspC-specific IS started on either
day 10, 20 or 40 p.i. In contrast, spirochetes were re-
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Figure 2. Kinetics of serum OspC-specific IgG Ab after pas-
sive (A) or active (B) immunization with GST-OspC. (A)
BALB/c mice were infected s.c. with 103 ZS7 spirochetes.
Ten days later the animals were injected with syngenic IS
specific for GST-OspC (30 ? g Ab/mouse, i.p., 4×, 3-day
intervals; open circles). Control mice remained untreated
(closed circles). The arrows indicate the time of serum
administration. Pooled sera (five mice/group) were taken at
indicated times and the levels of OspC-specific IgG Ab were
determined by ELISA. (B) Naive AKR/N mice were immu-
nized with GST-OspC in adjuvant (10 ? g Ab/mouse, s.c., 3×,
7-day intervals). Serum samples from three individual mice
(open squares, triangles and diamonds, respectively) were
collected at indicated time intervals and the levels of OspC-
specific Ab were determined by OspC-specific ELISA.
                                                                                                                                                                        
                                                                                                      
isolated from four of five untreated, but infected mice 
when examined between days 42–58 and days 65–73
p.i., respectively. Similar results were obtained with
BALB/c mice previously challenged by tick infection
(Table4).
2.3 Effect of active immunization with GST-OspC
on prevention and resolution of B. burg-
dorferi-induced disease and infection in
AKR/N mice
We next tested whether active immunization with GST-
OspC is practicable to prevent or treat B. burgdorferi
infection in AKR/N mice. These animals not only develop
persistent spirochetal infection, but also clinical arthritis
(Table 5, and [24]). In view of the fact that both quality and
quantity (Tables1 and 3; Fig.1; [16]) of GST-OspC-specific
Ab are important for their therapeutic efficacy, we first
analyzed the kinetics of specific IgG Ab production gener-
ated upon immunization of naive AKR/N mice with GST-
OspC (Fig. 2B). Only marginal amounts of OspC-specific
IgG Ab (0.4 ? g/ml) were detectable in one of three mice
tested within the first 7 days after priming. Significantly
more IgG Ab (125.9 ± 64.6 ? g/ml) were seen on day14 fol-
lowing the first boost (day 7), with peak responses (410.4
± 217.8 ? g/ml) at day 21 after the second boost (day 14),
and subsequent decline. However, concentrations of up
to 32.2 ± 16.7 ? g/ml OspC-specific IgG Ab were detect-
able for more than 100 days after immunization.
Groups of four to five mice were immunized with GST-
OspC in adjuvant s.c. either 30days before or 1, 10, 22 or
60days after experimental infection with 103 spirochetes.
Table 4. Prevention and resolution of experimental or tick-
borne B. burgdorferi infection in BALB/c mice by passive
transfer of GST-OspC-specific mouse immune seruma)
Infection
route
Intervals of IS
transfer
(days p. i.)
Dose
( ? g/mouse)
Ear culture
(days p. i.)
42–58 65–73
Syringe
inoculation
None 4/5 3/5
–1 h 10 0/5 ND
10,13,16,19 30 1/5 ND
20,23,26,29 30 0/5 ND
40,43,46,49 30 ND 1/5
Tick-borne
infection
None 1/5 3/5
10,13,16,19 30 0/4 0/4
20,23,26,29 30 0/5 0/5
a) BALB/c mice were treated with OspC-specific mouse IS
either before (–1h) or starting at the indicated time points
p. i. (4×, 3-days intervals). Recipients were challenged
either experimentally with 103 cultured spirochetes (ZS7,
s.c.) or with previously infected (ZS7) nymphal ticks.
Control mice remained untreated.
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Control mice were either given rLip-OspA or remained
untreated. Serum titers of anti-OspA and anti-OspC Ab
were determined in individual mice before and/or after
immunization. As shown in Table 5, experimental infec-
tion of AKR/N mice alone led to the generation of anti-
OspC but not anti-OspA Ab, supporting previous studies
[6, 7, 25]. Upon immunization with GST-OspC, all 23 ani-
mals produced high amounts of OspC-specific Ab within
20–30 days post immunization, ranging from 38 to
129 ? g/ml, independent of their state of infection. Simi-
larly, all mice immunized with rLip-OspA generated high
amounts of OspA-specific Ab (397–2446 ? g Ab/ml).
Active immunization of AKR/N mice with either rLip-
OspA or GST-OspC prevented subsequent experimental
infection (Table 5). In contrast, when AKR/N mice were
immunized with either GST-OspC or rLip-OspA starting
at either day 1, 10, 22 or 60 p.i., no significant effect on
either the onset of clinical arthritis, which was first appar-
ent in infected control mice between days 20–25 p.i., or
Table 5. Prevention, but not resolution, of experimental B. burgdorferi infection in AKR/N mice by active immunization with
GST-OspCa)
Time of
immunization
(day)
Recombinant
vaccine
Anti-OspA IgG ( ? g/ml) Anti-OspC IgG ( ? g/ml) Clinical arthritis Ear culture
before
immuni-
zation
after
immuni-
zation
before
immuni-
zation
after
immuni-
zation
before
immuni-
zation
after
immuni-
zation
before
immuni-
zation
after
immuni-
zation
–30 None ND 0 ND 1.0±0.3 0/4 4/4 ND 4/4
rLip-OspA ND 677.6±41.2 ND 0.2±0.1 0/5 0/5 ND 0/5
GST-OspC ND 0.0±0.0 ND 37.8±25.5 0/5 0/5 ND 0/5
1 p. i. None ND 0.0±0.0 ND 10.9±5.2 0/5 3/5 ND 3/5
rLip-OspA ND 396.6±68.4 ND 10.1 ± 5.8 0/5 4/5 ND 4/5
GST-OspC ND 0.0±0.0 ND 105.2±52.6 0/5 4/5 ND 5/5
10 p. i. None ND 0.0±0.0 ND 7.6±3.6 0/5 4/5 ND 4/5
rLip-OspA ND 1463.5±738.0 ND 5.8±2.2 0/5 3/5 ND 3/5
GST-OspC ND 0.0±0.0 ND 90.8±54.0 0/5 4/5 ND 4/5
22 p. i. None 0.0±0.0 0.0±0.0 4.4±3.6 1.5±0.3 3/5 4/5 5/5 5/5
rLip-OspA 0.0±0.0 1480.0±248.1 8.7±3.5 1.3±0.3 2/3 3/3 2/3 3/3
GST-OspC 0.0±0.0 0.0±0.0 5.4±1.2 128.8±22.4 1/4 3/4 2/4 4/4
60 p. i. None 0.0±0.0 0.0±0.0 1.8±0.4 2.0±1.1 4/4 4/4 4/4 4/4
rLip-OspA 0.0±0.0 2446.3±606.0 1.1±0.7 0.7±0.7 4/4 1/4 4/4 4/4
GST-OspC 0.0±0.0 0.0±0.0 1.7±1.3 112.0±37.3 4/4 3/4 4/4 4/4
a) AKR/N mice were immunized with either GST-OspC or rLip-OspA (10 ? g/mouse, 3×, 7 days interval) at the indicated time
points. Control mice remained untreated. All mice were experimentally inoculated with 103 spirochetes (ZS7, s.c.). Clinical and
serological examinations as well as recultivation of spirochetes from ear biopsies were done both at the time points before
immunization and/or 20–30 days after the last antigen boost (exception: animals immunized 30 days before infection were
examined on day 62 p. i.).
on the course of an established clinical arthritis was seen.
In addition, with few exceptions none of the four immuni-
zation protocols led to clearance of spirochetes from the
infected mice. This cannot be due to an inherent inability
of OspC-specific Ab to target and kill spirochetes in vivo
since repeated passive transfer of GST-OspC-specific IS
(30 ? g Ab, 4×) from AKR/N mice into C.B-17 SCID mice at
day 22 p.i. led to substantial reduction of fully developed
clinical arthritis and to elimination of spirochetes within
10 days after the last treatment (data not shown).
In light of the notion that IgG isotypes express distinct
potentials to control B. burgdorferi infection [5, 8], we
compared the Ig isotypes of OspC-specific Ab in pooled
IS from infected and subsequently immunized AKR/N
mice with those from recipients which were either only
immunized with GST-OspC or experimentally infected
with 103 spirochetes. All IS were shown to contain OspC-
specific Ab of the Ig isotypes IgG1, IgG2a, IgG2b and
IgG3, though at varying quantities, irrespective of
6
Figure 3. Detection of ospA and OspC gene expression in tissue specimens from ear, heart and spleen of infected
C.B-17 SCID and AKR/N mice at indicated time intervals p.i. by RT-PCR (± reverse transcriptase), as described in Sect. 4.9.
whether mice were only infected or actively immunized
before (day 30) or after (day 1, 10, 22 or 60 p.i.) infection
(data not shown).
2.4 Kinetics of ospA and OspC gene expression
in infected tissues from infected mice
The efficacy of OspC-based therapeutic vaccination crit-
ically depends on the accessibility of spirochetes for Ab
and the level of OspC expression. To investigate the lat-
ter aspect, tissue specimens from infected mice were
analyzed for the presence of spirochetes and the expres-
sion of OspC-specific mRNA using reverse transcription
(RT)-PCR. As shown in Fig. 3, OspA- and OspC-specific
mRNA is readily detectable by RT-PCR in low passage
cultured spirochetes. The detection limit is 24–120 pg of
spirochete-specific cDNA ( ˚ 30–1200 spirochetes/
organ). After experimental infection of C.B-17 SCID and
AKR/N mice, OspC-specific mRNA could be amplified
from distant skin (ear) and heart biopsy specimes from
both mouse strains, at the early stage of infection
between days 25 and 45 p.i. When analyzed around
day 100 p.i., OspC-specific mRNA could still be ampli-
fied from ear, heart and also from spleen of C.B-17 SCID
mice. In contrast, at this time point p.i., OspC-
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specific transcripts were only detected in tissue samples
from ear, but not in those from heart or spleen of AKR/N
mice. Consistent with serological and molecular genetic
data [6, 7, 18, 25, 26], OspA-specific mRNA could not be
detected at all in any of the three target organs of both
mouse strains between days 45 and 100 p.i. In addition,
OspA- and OspC-specific mRNA could not be amplified
from the three target organs of uninfected control mice.
3 Discussion
The main findings of the present study are that (1) OspC
is consistently expressed by B. burgdorferi during infec-
tion in mice for at least 100 days p.i., (2) passive transfer
of OspC-specific Ab generated against GST-OspC pre-
vents and resolves disease and/or infection in both
experimentally and tick-infected immunocompromized
(C.B-17. SCID) and immunocompetent (BALB/c) mice,
and (3) active vaccination of AKR/N mice with recombi-
nant GST-OspC fusion protein is suitable to prevent, but
not to cure, B. burgdorferi infection.
From the two structural distinct forms of OspC tested,
i.e. GST-OspC and its derivative rOspC (lipid free), only
the former one elicits protective Ab against infection
(Table 1). This is not due to a differential immunogenicity
of the two antigen preparations, since both GST-OspC
and rOspC induced similar amounts of OspC-specific Ab
in mice. It is more likely that both recombinant mole-
cules, which only differ with respect to the GST domain,
exhibit distinct conformational epitopes and thus lead to
the induction of different arrays of Ab specificities. This
assumption is also supported by a recent observation
showing that protective OspC-specific Ab were only
induced by immunization with a crude Escherichia coli
lysate containing rOspC, but not with its denatured form,
in spite of similar immunogenicity [20]. At present, it is
not known to what extent the conformation of GST-OspC
corresponds to that of natural OspC and whether the
OspC-specific Ab produced during infection are protec-
tive at all. However, it is notable that all preparations of
recombinant OspC fusion proteins tested so far, includ-
ing those from European (Pko [11]), ZS7 ([16] and here)
and North American isolates (SON 188 [19], B31 [20]),
except one strain (N40 [21]), were able to induce protec-
tive Ab in mice. This was also true with Ab generated to
GST-OspC in rabbits. However, it became clear that the
biological activity of the Ab generated to individual
recombinant OspC preparations is not only dependent
on the immunogenicity of the antigen, but also critically
influenced by the nature of OspC as well as the genetic
background of the recipient. This is of importance for the
design of effective OspC vaccine formulations.
We have previously reported that polyclonal and mono-
specific mouse IS to GST-OspC resolve chronic arthritis
and carditis and clear spirochetes in experimentally
infected C.B-17 SCID mice [16]. The experiments pre-
sented now demonstrate that the same protocol is also
suitable to eliminate infection both from experimentally
and tick-inoculated immunocompetent BALB/c mice.
Spirochetes could not be recovered from most of the ear
biopsies of infected animals repeatedly treated with
OspC-specific IS starting at either days 10, 20 and 40
after syringe inoculation (18/20) or at days 10 or 20 after
tick-borne infection (0/9). This is in line with previous
reports [16, 18] and indicates that (1) spirochetes
express OspC during infection in mice, at least for the
time periods tested, independent of whether they were
introduced via needle or natural route and (2) that dis-
seminated spirochetes are accessible and susceptible to
elimination by OspC-specific Ab. These assumptions are
further supported by our findings that OspC-specific
mRNA was detectable in biopsy specimens from various
organs, including ear, heart and spleen, of immunodefi-
cient (C.B-17 SCID) and immunocompetent (AKR/N)
mice for up to 100 days p.i. The fact that none of the ex
vivo tissue samples contained OspA-specific mRNA cor-
roborates previous studies and emphasized that OspA is
not readily expressed during infection in mice [18, 25].
Active immunization of AKR/N mice with GST-OspC only
resulted in complete protection against subsequent
challenge with B. burgdorferi, but failed to clear or mod-
ulate established infections. This finding is surprising for
two reasons. Firstly, OspC-specific mRNA was observed
in tissue specimens from AKR/N ear and heart for up to
45 days p.i. and was still detectable in ear biopsy speci-
mens at day 94 p.i. Secondly, both protocols led to the
production of OspC-specific Ab at quantities exceeding
those required to resolve chronic B. burgdorferi infection
in passive transfer experiments. A general unresponsive-
ness of AKR/N mice to protection-inducing epitopes was
excluded by the above results regarding prevention of B.
burgdorferi infection in AKR/N mice and the finding that
OspC-specific IS from GST-OspC immunized but unin-
fected AKR/N mice were able to prevent and resolve
infection upon transfer into C.B-17 SCID mice (data not
shown). It is also unlikely that the different protective
potential observed with the two OspC-specific Ab popu-
lations generated before or after infection is due to dis-
tinct patterns of IgG isotypes, and thus distinct biological
activities. This is inferred from the data showing that sim-
ilar patterns of IgG isotypes, including those of IgG1,
IgG2a, IgG2b and IgG3, were generated in AKR/N mice
in response to GST-OspC, independent of the immuno-
logical history (data not shown). Thus, the failure to clear
an established infection in subsequently immunized
AKR/N mice may be due to a decreased surface expres-
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sion of OspC or to sequestration of B. burgdorferi, and
indicates that spirochetes residing in skin tissue are less
vulnerable to Ab-mediated destruction (see also below).
This is also interesting since skin seems to be the most
prominent tissue for isolation of B. burgdorferi sensu latu
from reservoir hosts on which ticks feed and from which
they get the infection [23, 27, 28].
The failure to resolve an established B. burgdorferi infec-
tion by active immunization with GST-OspC may also be
due to selection of Ab responses to GST-OspC by previ-
ous encounter with the native antigen during infection.
This phenomen of priming-induced deflection of anti-
body responses, termed “original antigenic sin”, was first
observed with humans vaccinated with influenza [29,
30]. In these studies the resulting Ab were shown to have
higher affinity for strains to which patients had been
exposed in childhood than for the vaccine strain. It was
subsequently revealed that the immunological response
was oriented toward cross-reactive epitopes within the
polymorphic viral hemagglutinin with simultaneous igno-
rance of additional epitopes present in the vaccine [31,
32]. Accordingly, Ab responses to GST-OspC in previ-
ously infected mice would also be expected to be mainly
directed to cross-reactive epitopes expressed on both
native and recombinant OspC protein and not to new
ones expressed by the recombinant GST-OspC protein.
The finding that protection by OspC-reactive Ab is only
achieved upon vaccination of naive, but not infected
mice with GST-OspC, suggests that the protective epi-
tope(s) is either not expressed on native OspC or not
immunogenic during an ongoing infection. This by itself
is of significance for the survival of B. burgdorferi in an
immunocompetent environment. If this non-
responsiveness to protection-inducing epitopes is due to
clonal imprinting, injudicious vaccine design will cause
problems because of the potential suppression of pro-
tective immune responses caused by the pathogen
itself. Only the presentation of a synthetic vaccine lack-
ing those OspC epitopes to which the immune system
has been imprinted would circumvent this dilemma.
Taken together, the results presented here demonstrate
that passive vaccination with OspC Ab is suitable to pre-
vent and cure experimental and tick-borne B. burgdorferi
infection in mice. This reveals a previously unrecognized
role for OspC in protective immunity against B. burgdor-
feri infection and may have important implications for the
development of new prophylactic and therapeutic strate-
gies against human Lyme disease.
                                                                   
4 Materials and methods
4.1 Animals
Adult female mice of strains AKR/N (H-2k), BALB/c (H-2d)
and C.B-17 SCID (H-2d) were bred under SPF conditions at
the Max-Planck-Institut für Immunbiologie, Freiburg, Ger-
many. Animals between 6 and 8 weeks of age were used
throughout the experiments.
4.2 Spirochetes and infection of mice with
B. burgdorferi
The virulent low-passage (two to four in vitro passages) tick
isolate B. burgdorferi ZS7 was grown in Barbour-Stoenner-
Kelly medium at 32 °C for 48–72 h and harvested as
described [33]. Animals were challenged either by needle
inoculation with 1×103 viable B. burgdorferi organisms (s.c.)
or by previously infected Ixodes ricinus nymphs, as
described [34].
4.3 Recombinant antigens
A full-length rLip-OspA from B. burgdorferi strain ZS7 was
generated as described [35] and was kindly provided by
SmithKline Beecham, Rixensart, Belgium. GST-OspC from
B. burgdorferi strain ZS7 was generated using established
protocols [36]. rOspC was generated by cleaving the GST-
OspC fusion protein with thrombin.
4.4 Polyclonal immune sera to recombinant antigens
BALB/c mice were repeatedly inoculated with either 10 ? g of
rLip-OspA, GST-OspC, rOspC or GST in 100 ? l ABM2 adju-
vant (Sebak, Aldenbach, Germany) as described [16]. Rab-
bits (Chinchilla-Bastard) were injected with 400 ? g GST-
OspC in CFA, directly into popliteal lymph nodes and 200 ? g
of the same antigen preparation into multiple s.c. sites of the
rabbit and boosted once 4 weeks later by injecting 700 ? g of
the same antigen preparation into multiple s.c. sites. OspA-
or OspC-specific Ab were determined with ELISA using
either rLip-OspA or rOspC as substrates.
4.5 Analysis of serum Ab by ELISA and Western blot
Serum Ab to B. burgdorferi, OspA or OspC were quantified
by a solid-phase ELISA as described [37] using as sub-
strates either 10 mg/ml of B. burgdorferi lysate or 1 ? g/ml of
either rLip-OspA (ZS7) or rOspC (ZS7). Western blot analy-
sis, using whole-cell lysate of B. burgdorferi strain ZS7 as
antigen preparation, was done as described [9].
Isotypes of OspC-specific Ab (IgM, IgG, IgG1, IgG2a, IgG2b
and IgG3) were analyzed by Western blot as described [37],
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with the modification that rOspC was used as antigen
instead of spirochetal lysate. To compare the relative
amounts of OspC-specific isotypes in individual serum sam-
ples, IS tested were adjusted to contain 200 ng of total
OspC-specific Ab for each nitrocellulose strip.
4.6 Passive immunization
C.B-17 SCID and BALB/c immunocompetent mice were
either injected i.p. with IS (in some cases with OspA-specific
IS) 1h before infection or were left untreated. Alternatively,
mice were first infected s.c. and subsequently given repeat-
edly (4× at 3–4 day intervals) various amounts of polyclonal
IS specific for either OspA or OspC (i.p.) at indicated time
points relative to infection. C.B-17 SCID mice were moni-
tored for the development of clinical arthritis in the tibiotarsal
joints under double-blind conditions. The severity of arthritis
was scored in the right and left tibiotarsal joint [16]. The sta-
tus of infection of disease-resistant BALB/c mice was deter-
mined by testing for the outgrowth of viable spirochetes
from cultured biopsies, as described [22].
4.7 Active immunization
AKR/N mice were immunized s.c. with rLip-OspA or GST-
OspC (10 ? g/mouse, 3×, in 7-day intervals) either before
infection or at the indicated time point after experimental
infection with culture-derived spirochetes. The course of dis-
ease and infection was monitored by determining the sever-
ity of clinical arthritis and by testing the outgrowth of viable
spirochetes from cultured ear biopsies, as described [16].
4.8 Histology
For histopathological examination, C.B-17 SCID mice were
killed at indicated time points p.i. Heart tissues were fixed in
10 % formaldehyde, embedded in paraffin and stained with
hematoxylin and eosin. Samples were examined under
double-blind conditions. For comparison of the histopatho-
logical alterations, in particular, cellular infiltrations, the fol-
lowing scoring system was used: ++, extensive; +, severe;
±, moderate; –, no lesion.
4.9 Detection of ospA- and OspC-specific mRNA in
biopsies by RT-PCR
Untreated and infected C.B-17 SCID and AKR/N mice were
killed at indicated time points. Total RNA was isolated from
two entire ears, half of the heart and one third of the spleen
of individual mice by using RNAClean reagent (AGS GmbH,
Heidelberg, Germany). After treatment with DNase (Pro-
mega, Madison, WI), 15 ? g of ear RNA, 10 ? g of heart RNA
and 15 ? g of spleen RNA were incubated with reverse tran-
scriptase and random hexamer primers (Pharmacia,
Uppsala, Sweden) to complementary DNA (cDNA) using the
Superscipt II RT kit (Gibco-BRL, Gaithersburg, MD).
Because of overlapping bands generated by random prim-
ers, heart RNA (5 ? g) was transcribed using a 3’ OspA primer
(sequence see below). As control for DNA contamination,
identical first-strand synthesis reactions were performed in
the absence of reverse transcriptase. To verify the success
of each RT reaction, a cDNA equivalent to 50 ng of mouse
tissue RNA was amplified by PCR using oligonucleotide
primers for the HPRT gene: 5’-GCT GGT GAA AAG GAC
CTC T-3’; and 5’-CAC AGG ACT AGA ACA CCT GC-3’. For
amplification of ospA- and OspC-specific mRNA, cDNA
equivalent to 2 mg of total RNA were added, which repre-
sented 1/25 ear RNA, 1/70 heart RNA and 1/210 spleen
RNA. Sequences of 5’ and 3’ primers for ospA are: 5’-GGG
AAT AGG TCT AAT ATT AGC C-3’; 5’-TGC CTG AAT TCC
AAG CTG CA-3’; for OspC gene: 5’-CTG ATG AGT CTG TTA
AAG GGC C-3’; 5’TTA CCA AGA CTT GCG TGC TC-3’.
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